Relay Therapeutics Net Income
| RLAY Stock | USD 8.96 0.31 3.58% |
As of the 10th of February, Relay Therapeutics holds the Risk Adjusted Performance of 0.087, semi deviation of 3.39, and Coefficient Of Variation of 1019.16. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Relay Therapeutics, as well as the relationship between them.
Relay Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 117.6462 | Revenue | Earnings Share (1.72) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -303.9 M | -319.1 M | |
| Net Loss | -261.5 M | -274.5 M | |
| Net Loss | -303.9 M | -319.1 M | |
| Net Loss | (2.13) | (2.23) | |
| Net Income Per E B T | 0.79 | 0.70 |
Relay | Net Income | Build AI portfolio with Relay Stock |
The evolution of Net Income for Relay Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Relay Therapeutics compares to historical norms and industry peers.
Latest Relay Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Relay Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Relay Therapeutics financial statement analysis. It represents the amount of money remaining after all of Relay Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Relay Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Relay Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (337.71 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Relay Net Income Regression Statistics
| Arithmetic Mean | (147,947,898) | |
| Coefficient Of Variation | (92.32) | |
| Mean Deviation | 125,817,162 | |
| Median | (48,785,000) | |
| Standard Deviation | 136,587,569 | |
| Sample Variance | 18656.2T | |
| Range | 315.1M | |
| R-Value | (0.82) | |
| Mean Square Error | 6412.1T | |
| R-Squared | 0.68 | |
| Significance | 0.000049 | |
| Slope | (22,268,299) | |
| Total Sum of Squares | 298498.6T |
Relay Net Income History
Other Fundumenentals of Relay Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Relay Therapeutics Net Income component correlations
Relay Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Relay Therapeutics is extremely important. It helps to project a fair market value of Relay Stock properly, considering its historical fundamentals such as Net Income. Since Relay Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Relay Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Relay Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relay Therapeutics. Anticipated expansion of Relay directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Relay Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.72) | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets | Return On Equity |
The market value of Relay Therapeutics is measured differently than its book value, which is the value of Relay that is recorded on the company's balance sheet. Investors also form their own opinion of Relay Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relay Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relay Therapeutics' market value can be influenced by many factors that don't directly affect Relay Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Relay Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Relay Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Relay Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Relay Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Relay Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Relay Therapeutics.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Relay Therapeutics on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Relay Therapeutics or generate 0.0% return on investment in Relay Therapeutics over 90 days. Relay Therapeutics is related to or competes with Syndax Pharmaceuticals, Oric Pharmaceuticals, Amylyx Pharmaceuticals, Inhibrx Biosciences, Upstream Bio, Nektar Therapeutics, and Immatics. Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company More
Relay Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Relay Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Relay Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.67 | |||
| Information Ratio | 0.0768 | |||
| Maximum Drawdown | 30.68 | |||
| Value At Risk | (5.45) | |||
| Potential Upside | 6.4 |
Relay Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Relay Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Relay Therapeutics' standard deviation. In reality, there are many statistical measures that can use Relay Therapeutics historical prices to predict the future Relay Therapeutics' volatility.| Risk Adjusted Performance | 0.087 | |||
| Jensen Alpha | 0.3727 | |||
| Total Risk Alpha | (0.07) | |||
| Sortino Ratio | 0.0965 | |||
| Treynor Ratio | 0.5592 |
Relay Therapeutics February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.087 | |||
| Market Risk Adjusted Performance | 0.5692 | |||
| Mean Deviation | 3.25 | |||
| Semi Deviation | 3.39 | |||
| Downside Deviation | 3.67 | |||
| Coefficient Of Variation | 1019.16 | |||
| Standard Deviation | 4.61 | |||
| Variance | 21.28 | |||
| Information Ratio | 0.0768 | |||
| Jensen Alpha | 0.3727 | |||
| Total Risk Alpha | (0.07) | |||
| Sortino Ratio | 0.0965 | |||
| Treynor Ratio | 0.5592 | |||
| Maximum Drawdown | 30.68 | |||
| Value At Risk | (5.45) | |||
| Potential Upside | 6.4 | |||
| Downside Variance | 13.48 | |||
| Semi Variance | 11.47 | |||
| Expected Short fall | (3.78) | |||
| Skewness | 1.38 | |||
| Kurtosis | 5.09 |
Relay Therapeutics Backtested Returns
Relay Therapeutics appears to be slightly risky, given 3 months investment horizon. Relay Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of 0.15, which implies the firm had a 0.15 % return per unit of risk over the last 3 months. By analyzing Relay Therapeutics' technical indicators, you can evaluate if the expected return of 0.72% is justified by implied risk. Please evaluate Relay Therapeutics' Semi Deviation of 3.39, risk adjusted performance of 0.087, and Coefficient Of Variation of 1019.16 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Relay Therapeutics holds a performance score of 12. The company holds a Beta of 0.79, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Relay Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Relay Therapeutics is expected to be smaller as well. Please check Relay Therapeutics' value at risk, as well as the relationship between the kurtosis and market facilitation index , to make a quick decision on whether Relay Therapeutics' historical price patterns will revert.
Auto-correlation | 0.03 |
Virtually no predictability
Relay Therapeutics has virtually no predictability. Overlapping area represents the amount of predictability between Relay Therapeutics time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Relay Therapeutics price movement. The serial correlation of 0.03 indicates that only 3.0% of current Relay Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.03 | |
| Spearman Rank Test | 0.17 | |
| Residual Average | 0.0 | |
| Price Variance | 0.2 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Relay Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Relay Therapeutics reported net income of (337.71 Million). This is 198.95% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 159.15% higher than that of the company.
Relay Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Relay Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Relay Therapeutics could also be used in its relative valuation, which is a method of valuing Relay Therapeutics by comparing valuation metrics of similar companies.Relay Therapeutics is currently under evaluation in net income category among its peers.
Relay Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Relay Therapeutics from analyzing Relay Therapeutics' financial statements. These drivers represent accounts that assess Relay Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Relay Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 2.9B | 1.7B | 1.3B | 588.6M | 529.8M | 503.3M | |
| Enterprise Value | 2.7B | 735.6M | 1.3B | 512.8M | 461.5M | 438.5M |
Relay Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Relay Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Relay Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Relay Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Relay Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Relay Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Relay Therapeutics' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 3.2 M | Kynam Capital Management, Lp | 2025-06-30 | 2.9 M | T. Rowe Price Associates, Inc. | 2025-06-30 | 2.9 M | Dimensional Fund Advisors, Inc. | 2025-06-30 | 2.8 M | Mpm Oncology Impact Management Lp | 2025-06-30 | 2.3 M | Goldman Sachs Group Inc | 2025-06-30 | 1.9 M | Millennium Management Llc | 2025-06-30 | 1.9 M | Alphabet Inc | 2025-06-30 | 1.6 M | Renaissance Technologies Corp | 2025-06-30 | 1.5 M | Sb Investment Advisers (uk) Ltd | 2025-06-30 | 27.9 M | Blackrock Inc | 2025-06-30 | 14 M |
Relay Fundamentals
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (38.87) % | ||||
| Current Valuation | 982.93 M | ||||
| Shares Outstanding | 173.32 M | ||||
| Shares Owned By Insiders | 1.30 % | ||||
| Shares Owned By Institutions | 98.11 % | ||||
| Number Of Shares Shorted | 22.38 M | ||||
| Price To Book | 2.54 X | ||||
| Price To Sales | 184.90 X | ||||
| Revenue | 10.01 M | ||||
| Gross Profit | (259.24 M) | ||||
| EBITDA | (380.21 M) | ||||
| Net Income | (337.71 M) | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 8.72 X | ||||
| Total Debt | 48.5 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 15.22 X | ||||
| Book Value Per Share | 3.52 X | ||||
| Cash Flow From Operations | (249.11 M) | ||||
| Short Ratio | 10.46 X | ||||
| Earnings Per Share | (1.72) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 14.55 | ||||
| Number Of Employees | 188 | ||||
| Beta | 1.62 | ||||
| Market Capitalization | 1.54 B | ||||
| Total Asset | 871.3 M | ||||
| Retained Earnings | (1.74 B) | ||||
| Working Capital | 758.48 M | ||||
| Net Asset | 871.3 M |
About Relay Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Relay Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relay Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relay Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.